Tarsus Pharmaceuticals Inc
$ 81.83
-0.06%
04 Dec - close price
- Market Cap 3,475,732,000 USD
- Current Price $ 81.83
- High / Low $ 82.90 / 80.14
- Stock P/E N/A
- Book Value 7.89
- EPS -1.99
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.12 %
- ROE -0.28 %
- 52 Week High 83.47
- 52 Week Low 38.51
About
Tarsus Pharmaceuticals, Inc. is an innovative clinical-stage biopharmaceutical company headquartered in Irvine, California, dedicated to developing groundbreaking therapies for ophthalmic diseases. The company's robust pipeline includes promising candidates specifically targeting dry eye disease and other vision-related disorders, addressing significant unmet medical needs within the ophthalmic market. Leveraging strong clinical development efforts, Tarsus is poised to enhance patient outcomes while positioning itself for sustained growth within the evolving landscape of eye care solutions.
Analyst Target Price
$86.11
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 | 2023-08-10 | 2023-05-09 | 2023-03-13 |
| Reported EPS | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 | -0.88 | -0.49 |
| Estimated EPS | -0.3645 | -0.38 | -0.63 | -0.8157 | -0.94 | -0.92 | -1.2 | -1.36 | -1.37 | -1.08 | -0.94 | -0.69 |
| Surprise | 0.0645 | -0.1 | -0.01 | 0.2157 | 0.33 | 0.04 | 0.19 | 0.05 | 0.09 | -0.09 | 0.06 | 0.2 |
| Surprise Percentage | 17.6955% | -26.3158% | -1.5873% | 26.4435% | 35.1064% | 4.3478% | 15.8333% | 3.6765% | 6.5693% | -8.3333% | 6.383% | 28.9855% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2025-10-20 21:32:39
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is nearing profitability, with analysts projecting a break-even point by 2026 and a profit of US$42m. The biopharmaceutical company, with a US$1.8b market cap, has reduced its losses and is expected to achieve significant year-on-year growth in revenue. Its prudent capital management, with low debt, also contributes to a positive outlook for investors.
2025-10-20 21:32:39
Tarsus Pharmaceuticals, Inc. (TARS) reported a Q2 loss of $0.48 per share, missing the Zacks Consensus Estimate, but exceeded revenue estimates with $102.66 million. Despite underperforming the market year-to-date, the company has surpassed consensus EPS estimates three times and revenue estimates four times in the last four quarters. Investors are advised to monitor management's commentary and future estimate revisions, as the stock currently holds a Zacks Rank #4 (Sell).
2025-10-20 21:32:39
HC Wainwright & Co. has increased its price target for Tarsus Pharmaceuticals (TARS) to $88.00 from $72.00, reiterating a 'Buy' rating. This update reflects a positive outlook on the company's future performance and aligns with recent favorable evaluations from other analysts. Tarsus Pharmaceuticals, a biopharmaceutical company focusing on eye care, continues to receive strong recommendations from market analysts.
2025-10-20 21:32:39
Tarsus Pharmaceuticals (TARS) saw its shares surge due to strong investor optimism surrounding Xdemvy, its prescription eye drop for Demodex blepharitis, and advancements in its pipeline. The company is diversifying its product offerings with mid-stage clinical trials for TP-04 and TP-05, targeting ocular rosacea and Lyme disease. Despite the positive outlook, investors are cautioned to monitor Xdemvy's adoption rates and potential future margin pressures.
2025-10-20 21:32:39
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares have surged 41% in the last month and 99% over the past year, leading to a high price-to-sales (P/S) ratio of 10.4x. This elevated P/S multiple is justified by the company's strong historical revenue growth and robust future revenue forecasts, with analysts predicting 42% annual growth for the next three years, significantly exceeding the industry average of 30%. Investors appear to be optimistic about Tarsus Pharmaceuticals' future prospects.
2025-10-20 21:32:39
H.C. Wainwright has increased its price target for Tarsus Pharmaceuticals to $88 from $72. This adjustment reflects an updated valuation for the company's stock.
